Inclusion Criteria:  18 to 80 years old; be diagnosed with CTO; CTO located in an epicardial coronary artery with a reference diameter of ≥ 2.5mm; comply with all the evaluations and follow-up protocols.  Exclusion Criteria:  suffered from acute myocardial infarction within the previous 3 months; rheumatic valvular disease; severe arrhythmia; lesions unsuitable for PCI; severely abnormal hematopoietic systems, such as platelet counts <100*10^9/L or > 700*10^9/L and white blood cell counts < 3*10^9/L; with active bleeding or bleeding tendencies(active ulcers, short-term ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions, recent craniocerebral trauma, and other bleeding or bleeding tendency); severe coexisting conditions, including severe renal function dysfunction [Glomerular filtration rate less than 60ml/min • 1.73 m2), severe hepatic dysfunction [glutamic-pyruvic transaminase (ALT) or glutamic-oxal acetic transaminase (ALT) elevated more than three times that of the upper limit of the normal reference], severe heart failure (NYHA classification III-IV), acute infectious diseases and immune disorders; tumors; surgery within 3 months; a life expectancy less than 12 months; pregnancy or planning to become pregnant; history of allergy or adverse reactions to aspirin, clopidogrel, ticagrelor, stains, contrast material, anticoagulant, or stents; cannot tolerate dual antiplatelet treatment; unable to communicate due to cognitive impairment, auditory, or visual impairment; participating in another trial for medication or an apparatus and in which the main endpoint has not been reached, or plan to participate in a clinical trial within 12 months of the intervention.